60 related articles for article (PubMed ID: 38563252)
1. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
Browne IM; André F; Chandarlapaty S; Carey LA; Turner NC
Lancet Oncol; 2024 Apr; 25(4):e139-e151. PubMed ID: 38547898
[TBL] [Abstract][Full Text] [Related]
2. Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients.
Niu J; Andres G; Kramer K; Kundranda MN; Alvarez RH; Klimant E; Parikh AR; Tan B; Staren ED; Markman M
Onco Targets Ther; 2015; 8():3323-8. PubMed ID: 26648736
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of
Peixoto A; Cirnes L; Carvalho AL; Andrade MJ; Brito MJ; Borralho P; Coimbra N; Borralho PM; Carneiro AS; Castro L; Correia L; Dionísio MR; Faria C; Figueiredo P; Gomes A; Paixão J; Pinheiro M; Prazeres H; Ribeiro J; Salgueiro N; Schmitt FC; Silva F; Silvestre AR; Sousa AC; Almeida-Tavares J; Teixeira MR; André S; Machado JC
Front Mol Biosci; 2023; 10():1082915. PubMed ID: 36825198
[No Abstract] [Full Text] [Related]
4. Corrigendum: Evaluation of
Peixoto A; Cirnes L; Carvalho AL; Andrade MJ; Maria José Brito ; Borralho P; Coimbra N; Borralho PM; Carneiro AS; Castro L; Correia L; Dionísio MR; Faria C; Figueiredo P; Gomes A; Paixão J; Pinheiro M; Prazeres H; Ribeiro J; Salgueiro N; Schmitt FC; Silva F; Silvestre AR; Sousa AC; Almeida-Tavares J; Teixeira MR; André S; Machado JC
Front Mol Biosci; 2024; 11():1298522. PubMed ID: 38721275
[TBL] [Abstract][Full Text] [Related]
5. Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter].
Syahruddin FI; Prihantono ; Muis M
Breast Cancer (Dove Med Press); 2024; 16():221-222. PubMed ID: 38623391
[No Abstract] [Full Text] [Related]
6. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
7. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
8. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract][Full Text] [Related]
9. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
11. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
14. The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
Morrison L; Loibl S; Turner NC
Nat Rev Clin Oncol; 2024 Feb; 21(2):89-105. PubMed ID: 38082107
[TBL] [Abstract][Full Text] [Related]
15. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.
Ma J; Chan JJ; Toh CH; Yap YS
NPJ Breast Cancer; 2023 Sep; 9(1):74. PubMed ID: 37684290
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
